Tiagabine
- 1 October 1994
- Vol. 35 (s5) , S81-S84
- https://doi.org/10.1111/j.1528-1157.1994.tb05976.x
Abstract
Summary: Tiagabine (TGB), a specific γ-aminobutyric acid (GABA)-uptake inhibitor, is a potential new antiepileptic drug with a novel mechanism of action. In animal models of epilepsy as well as in a placebo-controlled trial in patients with complex partial seizures, TGB showed significant anticonvulsant effects. TGB was well tolerated by most patients.Keywords
This publication has 6 references indexed in Scilit:
- Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitorEuropean Journal of Pharmacology, 1991
- (R)‐N‐[4,4‐Bis(3‐Methyl‐2‐Thienyl)but‐3‐en‐1‐yl]Nipecotic Acid Binds with High Affinity to the Brain γ‐Aminobutyric Acid Uptake CarrierJournal of Neurochemistry, 1990
- β1‐Adrenoceptors mediate smooth muscle relaxation in mouse isolated tracheaBritish Journal of Pharmacology, 1990
- Blockade of audiogenic seizures by a GABA-uptake inhibitor, NO-328, in the genetically epilepsy-prone ratPublished by Springer Nature ,1990
- GABA synaptic mechanisms: Stereochemical and conformational requirementsMedicinal Research Reviews, 1988
- Gaba receptor pharmacology functional considerationsBiochemical Pharmacology, 1981